Biogen (BIIB)
(Delayed Data from NSDQ)
$236.72 USD
+2.59 (1.11%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $236.76 +0.04 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 761 - 780 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
What Was Supposed to Be a Quiet Week Turns Into a Busy Week
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12, raises hopes of improvement in growth prospects
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12, raises hopes of an improvement in growth prospects...
Provider: FIRST GLOBAL
Analyst: THOMAS K